Emtricitabine/tenofovir disoproxil fumarate vs Rilpivirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Emtricitabine/tenofovir disoproxil fumarate · Truvada

Marketed by Gilead Sciences

Approved in HIVsmall molecule combination
Partial signal

NCT00323544 · Phase 3 · completed

This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT07584122 (registry estimate)

Reported efficacy

The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. (met)

Result source: NCT00323544

Rilpivirine · Edurant

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Reliable signal

NCT00540449 · Phase 3 · completed

This was a large (690-participant), randomized, quadruple-blinded, active-controlled (efavirenz) phase 3 trial with a hard clinical endpoint (confirmed viral load <50 copies/mL). The pre-specified non-inferiority margin was clearly met, with the confidence interval for the treatment difference falling entirely within the allowed -12% boundary, so rilpivirine was shown to be as effective as efavirenz on the primary measure despite a somewhat higher rate of virologic failure and resistance emergence as a secondary finding.

Next expected readout: December 2028 · NCT07637877 (registry estimate)

Reported efficacy

Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%. (met)

Result source: NCT00540449

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEmtricitabine/​tenofovir disoproxil fumarateRilpivirine
HIV-1 RNA below 50 copies/mL (week 48)83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
5 other results
  • 85.2% vs 87.4% wk 48 · n 344 · Phase 3 · primary NCT01108510
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.9% vs 79.3% wk 96 · n 344 · Phase 3 · secondary NCT01108510
  • 72.1% vs 74.1% wk 144 · n 344 · Phase 3 · secondary NCT01108510
  • 71.6% vs 79.7% wk 192 · n 74 · Phase 3 · secondary NCT01108510
94% vs 94%vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
12 other results
  • 95% vs 96% wk 48 · n 252 · Phase 3 · primary NCT02429791
  • 93.7% vs 93.9% wk 48 · n 316 · Phase 3 · primary NCT02345252
  • 90% vs 92% wk 48 · n 438 · Phase 3 · primary NCT02345226
  • 85.8% vs 81.6% wk 48 · n 394 · Phase 3 · primary NCT01309243
  • 93.7% vs 89.9% wk 24 · n 317 · Phase 3 · primary NCT01252940
  • 97% vs 98% DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 89.2% vs 88.5% wk 96 · n 316 · Phase 3 · secondary NCT02345252
  • 85.2% vs 85.1% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 77.9% vs 72.4% wk 96 · n 394 · Phase 3 · secondary NCT01309243
  • 93.9% vs 96.2% wk 48 · n 213 · Phase 3 · secondary NCT01709084
  • 89.3% vs 92.1% wk 48 · n 317 · Phase 3 · secondary NCT01252940
  • 98% vs 96% wk 24 · n 252 · Phase 3 · secondary NCT02429791
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT003235440.6% vs 1%vs FTC/RPV/TDFwk 96 · n 316NCT02345252
3 other results
  • 0.7% vs 0.9% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 0.6% vs 0% wk 48 · n 316 · Phase 3 · secondary NCT02345252
  • 1.1% vs 0.9% wk 48 · n 438 · Phase 3 · secondary NCT02345226
CD4 count, change (week 48)224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
12 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 277 vs 287 wk 96 · n 300 · Phase 3 · secondary NCT01108510
  • 291 vs 256 wk 96 · n 121 · Phase 3 · secondary NCT00089505
  • 223 vs 256 wk 96 · n 249 · Phase 3 · secondary NCT00089505
  • 213 vs 219 wk 48 · n 313 · Phase 3 · secondary NCT01108510
  • 310 vs 332 wk 144 · n 275 · Phase 3 · secondary NCT01108510
  • 191 vs 172 wk 48 · n 121 · Phase 3 · secondary NCT00089505
  • 172 vs 172 wk 48 · n 249 · Phase 3 · secondary NCT00089505
  • 350 vs 343 wk 192 · n 73 · Phase 3 · secondary NCT01108510
  • 158 vs 146 wk 48 · n 424 · Phase 4 · secondary NCT01380080
  • 96 vs 102 wk 24 · n 424 · Phase 4 · secondary NCT01380080
  • 8 vs 34 wk 48 · n 135 · Phase 4 · secondary NCT00724711
28 vs 18.4vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
14 other results
  • 42 vs 42.4 DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 12 vs 16 wk 96 · n 283 · Phase 3 · secondary NCT02345252
  • 12 vs 6 wk 96 · n 370 · Phase 3 · secondary NCT02345226
  • 278 vs 259 wk 96 · n 327 · Phase 3 · secondary NCT01309243
  • 32.3 vs 41.8 wk 48 · n 252 · Phase 3 · secondary NCT02429791
  • 9 vs -1 wk 48 · n 296 · Phase 3 · secondary NCT02345252
  • 23 vs 12 wk 48 · n 390 · Phase 3 · secondary NCT02345226
  • 10 vs -7 wk 48 · n 287 · Phase 3 · secondary NCT01252940
  • 200 vs 191 wk 48 · n 357 · Phase 3 · secondary NCT01309243
  • 16.2 vs 47.4 wk 24 · n 252 · Phase 3 · secondary NCT02429791
  • 20 vs 32 wk 24 · n 298 · Phase 3 · secondary NCT01252940
  • 145.9 vs 159.8 25 mg · wk 96 · n 93 · Phase 2 · secondary NCT00110305
  • 158.9 vs 159.8 150 mg · wk 96 · n 91 · Phase 2 · secondary NCT00110305
  • 172 vs 159.8 75 mg · wk 96 · n 95 · Phase 2 · secondary NCT00110305

HIV-1 RNA below 50 copies/mL (week 48)

Emtricitabine/​tenofovir disoproxil fumarate
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
5 other results
  • 85.2% vs 87.4% wk 48 · n 344 · Phase 3 · primary NCT01108510
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.9% vs 79.3% wk 96 · n 344 · Phase 3 · secondary NCT01108510
  • 72.1% vs 74.1% wk 144 · n 344 · Phase 3 · secondary NCT01108510
  • 71.6% vs 79.7% wk 192 · n 74 · Phase 3 · secondary NCT01108510
Rilpivirine
94% vs 94%vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
12 other results
  • 95% vs 96% wk 48 · n 252 · Phase 3 · primary NCT02429791
  • 93.7% vs 93.9% wk 48 · n 316 · Phase 3 · primary NCT02345252
  • 90% vs 92% wk 48 · n 438 · Phase 3 · primary NCT02345226
  • 85.8% vs 81.6% wk 48 · n 394 · Phase 3 · primary NCT01309243
  • 93.7% vs 89.9% wk 24 · n 317 · Phase 3 · primary NCT01252940
  • 97% vs 98% DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 89.2% vs 88.5% wk 96 · n 316 · Phase 3 · secondary NCT02345252
  • 85.2% vs 85.1% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 77.9% vs 72.4% wk 96 · n 394 · Phase 3 · secondary NCT01309243
  • 93.9% vs 96.2% wk 48 · n 213 · Phase 3 · secondary NCT01709084
  • 89.3% vs 92.1% wk 48 · n 317 · Phase 3 · secondary NCT01252940
  • 98% vs 96% wk 24 · n 252 · Phase 3 · secondary NCT02429791

HIV-1 RNA 50 copies/mL or more (week 48)

Emtricitabine/​tenofovir disoproxil fumarate
—Not posted · NCT00323544
Rilpivirine
0.6% vs 1%vs FTC/RPV/TDFwk 96 · n 316NCT02345252
3 other results
  • 0.7% vs 0.9% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 0.6% vs 0% wk 48 · n 316 · Phase 3 · secondary NCT02345252
  • 1.1% vs 0.9% wk 48 · n 438 · Phase 3 · secondary NCT02345226

CD4 count, change (week 48)

Emtricitabine/​tenofovir disoproxil fumarate
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
12 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 277 vs 287 wk 96 · n 300 · Phase 3 · secondary NCT01108510
  • 291 vs 256 wk 96 · n 121 · Phase 3 · secondary NCT00089505
  • 223 vs 256 wk 96 · n 249 · Phase 3 · secondary NCT00089505
  • 213 vs 219 wk 48 · n 313 · Phase 3 · secondary NCT01108510
  • 310 vs 332 wk 144 · n 275 · Phase 3 · secondary NCT01108510
  • 191 vs 172 wk 48 · n 121 · Phase 3 · secondary NCT00089505
  • 172 vs 172 wk 48 · n 249 · Phase 3 · secondary NCT00089505
  • 350 vs 343 wk 192 · n 73 · Phase 3 · secondary NCT01108510
  • 158 vs 146 wk 48 · n 424 · Phase 4 · secondary NCT01380080
  • 96 vs 102 wk 24 · n 424 · Phase 4 · secondary NCT01380080
  • 8 vs 34 wk 48 · n 135 · Phase 4 · secondary NCT00724711
Rilpivirine
28 vs 18.4vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
14 other results
  • 42 vs 42.4 DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 12 vs 16 wk 96 · n 283 · Phase 3 · secondary NCT02345252
  • 12 vs 6 wk 96 · n 370 · Phase 3 · secondary NCT02345226
  • 278 vs 259 wk 96 · n 327 · Phase 3 · secondary NCT01309243
  • 32.3 vs 41.8 wk 48 · n 252 · Phase 3 · secondary NCT02429791
  • 9 vs -1 wk 48 · n 296 · Phase 3 · secondary NCT02345252
  • 23 vs 12 wk 48 · n 390 · Phase 3 · secondary NCT02345226
  • 10 vs -7 wk 48 · n 287 · Phase 3 · secondary NCT01252940
  • 200 vs 191 wk 48 · n 357 · Phase 3 · secondary NCT01309243
  • 16.2 vs 47.4 wk 24 · n 252 · Phase 3 · secondary NCT02429791
  • 20 vs 32 wk 24 · n 298 · Phase 3 · secondary NCT01252940
  • 145.9 vs 159.8 25 mg · wk 96 · n 93 · Phase 2 · secondary NCT00110305
  • 158.9 vs 159.8 150 mg · wk 96 · n 91 · Phase 2 · secondary NCT00110305
  • 172 vs 159.8 75 mg · wk 96 · n 95 · Phase 2 · secondary NCT00110305
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Emtricitabine/tenofovir disoproxil fumarate: 4 of 4 rows · Rilpivirine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEmtricitabine/​tenofovir disoproxil fumarateRilpivirine
Dropout rate
24.7%a
NCT00458393 · Phase 3
show 15 more results
16%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
24%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
20%
NCT01380080 · Phase 4 · registry result, not featured evidence
—
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
0%200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
—Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
—
NCT00323492 · Phase 4 · registry result, not featured evidence
24.2%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
79.9%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
25%
NCT01195467 · Phase 3 · registry result, not featured evidence
19.5%
NCT00625404 · Phase 3 · registry result, not featured evidence
25.5%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
7.4%NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
8.4%NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
24.3%b
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
20%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
5.2%DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
6.1%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.5%
NCT01709084 · Phase 3 · registry result, not featured evidence
22.3%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
25.2%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
12.7%FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
15.7%FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
8.1%
NCT01252940 · Phase 3 · registry result, not featured evidence
21%
NCT01309243 · Phase 3 · registry result, not featured evidence
0%
NCT04012931 · Phase 2 · registry result, not featured evidence
30.6%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
40%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
33.3%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
12.1%
NCT02165202 · Phase 2 · registry result, not featured evidence
4%
NCT01286740 · Phase 2 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
7.1%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT00458393 · Phase 3
show 15 more results
0%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
8%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
—
NCT01380080 · Phase 4 · registry result, not featured evidence
—
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
—200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
—Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
—
NCT00323492 · Phase 4 · registry result, not featured evidence
1.6%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
7.4%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
—
NCT01195467 · Phase 3 · registry result, not featured evidence
—
NCT00625404 · Phase 3 · registry result, not featured evidence
5%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
—NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
—NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
3.5%b
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
5.3%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
2.4%DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
4.2%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT01709084 · Phase 3 · registry result, not featured evidence
3%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
2.5%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
0.6%FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
1.1%FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
0.9%
NCT01252940 · Phase 3 · registry result, not featured evidence
3%
NCT01309243 · Phase 3 · registry result, not featured evidence
—
NCT04012931 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—
NCT02165202 · Phase 2 · registry result, not featured evidence
—
NCT01286740 · Phase 2 · registry result, not featured evidence
—50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
—
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
7.5%a
NCT00458393 · Phase 3
show 15 more results
0%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
0%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
20%
NCT01380080 · Phase 4 · registry result, not featured evidence
7.7%
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
—200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
0%Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
9.7%
NCT00323492 · Phase 4 · registry result, not featured evidence
11.7%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
9.6%1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
18.6%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
10%
NCT01195467 · Phase 3 · registry result, not featured evidence
3.2%
NCT00625404 · Phase 3 · registry result, not featured evidence
20.3%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
7.4%NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
10.4%NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
11.6%b
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
9.4%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
—DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
3.2%DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
13.5%DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
4%DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
5.8%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
14.6%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.3%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.5%
NCT01709084 · Phase 3 · registry result, not featured evidence
4.4%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
7.6%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
11.4%FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
5.3%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
0%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
12.3%FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
4.8%Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
0%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
6.6%
NCT01252940 · Phase 3 · registry result, not featured evidence
9.1%
NCT01309243 · Phase 3 · registry result, not featured evidence
0%
NCT04012931 · Phase 2 · registry result, not featured evidence
16.7%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
4.4%
NCT02165202 · Phase 2 · registry result, not featured evidence
2%
NCT01286740 · Phase 2 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
0%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
pharyngitis 20.2% (placebo 22.9%)
parasitic infection intestinal 18.8% (placebo 17.6%)
alanine aminotransferase increased 12.3% (placebo 12.6%)
NCT00458393 · Phase 3
show 13 more results
erectile dysfunction 4.8%
gastroenteritis 4.8%
headache 4.8%
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
gastroenteritis 5.3%
pulmonary embolism 5.3%
anxiety 0%
NCT02401230 · Phase 4 · registry result, not featured evidence
neutrophil count decreased 38%
blood albumin decreased 35.6%
blood sodium decreased 34%
NCT01380080 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 9%
diarrhea 8.4%
cough 5.2%
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 9.7%
abdominal pain 4.2%
bronchitis 4.2%
NCT00323492 · Phase 4 · registry result, not featured evidence
100 mg
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · registry result, not featured evidence
1200 mg QD + Truvada
headache 15.8%
nausea 13.6%
diarrhoea 13.4%
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 22.1%
jaundice 22.1%
ocular icterus 20.1%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
bilateral arm pain 2.5%
cellulitis 2.5%
diarrhoea 2.5%
NCT01195467 · Phase 3 · registry result, not featured evidence
blood phosphorus decreased 19.4% (placebo 18.3%)
aspartate aminotransferase increased 13.1% (placebo 11.5%)
headache 13.1% (placebo 14.3%)
NCT00625404 · Phase 3 · registry result, not featured evidence
400 mg b.i.d.
nasopharyngitis 26.7%
headache 26%
diarrhoea 25.6%
NCT00369941 · Phase 3 · registry result, not featured evidence
cough 23.1%
neutrophil count decreased 23.1%
rash 23.1%
NCT00089505 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 27.3%
rash 26.5%
cough 24.1%
NCT00089505 · Phase 3 · registry result, not featured evidence
b
upper respiratory tract infection 15.3%
diarrhoea 14.7%
headache 14.5%
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 28 more results
headache 17.9%
nausea 16.8%
nasopharyngitis 14.7%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
arthralgia 0%
back pain 0%
bronchitis 0%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 20.6%
headache 14.7%
diarrhoea 13.9%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.7%
headache 9.5%
diarrhoea 8.7%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
arthralgia 0%
asthenia 0%
back pain 0%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
nasopharyngitis 18.4%
upper respiratory tract infection 14.2%
bronchitis 10.7%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
nasopharyngitis 8%
upper respiratory tract infection 7.3%
arthralgia 6.5%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 29.6%
headache 17.8%
urinary tract infection 13.6%
NCT01709084 · Phase 3 · registry result, not featured evidence
pregnancy 1.9%
headache 1.1%
alanine aminotransferase increased 0.8%
NCT01266902 · Phase 3 · registry result, not featured evidence
facial wasting 1.7%
hepatitis c 1.7%
hypertension 1.7%
NCT01266902 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.5%
upper respiratory tract infection 14.9%
diarrhoea 10.8%
NCT02345252 · Phase 3 · registry result, not featured evidence
back pain 10.5%
conjunctivitis allergic 10.5%
cough 10.5%
NCT02345252 · Phase 3 · registry result, not featured evidence
cough 17.6%
nasopharyngitis 17.6%
pyrexia 17.6%
NCT02345252 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 16.9%
nasopharyngitis 11.6%
cough 10.3%
NCT02345226 · Phase 3 · registry result, not featured evidence
cough 9.5%
diarrhoea 9.5%
eczema 9.5%
NCT02345226 · Phase 3 · registry result, not featured evidence
rhinitis 16%
nasopharyngitis 12%
bronchitis 8%
NCT02345226 · Phase 3 · registry result, not featured evidence
nasopharyngitis 11%
diarrhoea 10.7%
headache 9.8%
NCT01252940 · Phase 3 · registry result, not featured evidence
diarrhoea 17.5%
nausea 16.5%
upper respiratory tract infection 14.5%
NCT01309243 · Phase 3 · registry result, not featured evidence
vomiting 15.4%
alanine aminotransferase increased 11.5%
abdominal pain 7.7%
NCT04012931 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 55.6%
influenza 41.7%
cough 27.8%
NCT00799864 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 60%
toothache 40%
alanine aminotransferase increased 20%
NCT00799864 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 55.6%
decreased appetite 22.2%
diarrhoea 22.2%
NCT00799864 · Phase 2 · registry result, not featured evidence
15 mg
upper respiratory tract infection 100%
anaemia 50%
dermatitis atopic 50%
NCT00799864 · Phase 2 · registry result, not featured evidence
12.5 mg
upper respiratory tract infection 100%
cough 50%
lower respiratory tract infection 50%
NCT00799864 · Phase 2 · registry result, not featured evidence
injection site pain 75% (placebo 40.5%)
injection site pruritus 36.3% (placebo 11.9%)
injection site swelling 36.3% (placebo 7.1%)
NCT02165202 · Phase 2 · registry result, not featured evidence
diarrhoea 16.3%
upper respiratory tract infection 14.3%
insomnia 12.2%
NCT01286740 · Phase 2 · registry result, not featured evidence
50mg/25mg
headache 6.3%
vessel puncture site bruise 6.3%
vomiting 6.3%
NCT03984838 · Phase 1 · registry result, not featured evidence
insomnia 23.1%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Emtricitabine/tenofovir disoproxil fumarate

Cumulative Incidence of Death 4.8 vs 5.2 IPT Cumulative probability per 100 persons @ 24wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
Cumulative Incidence of Disease Progression 16.6 vs 11.3 IPT Cumulative probability per 100 persons @ 96wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV Disease Progression 17.1 vs 12.5 IPT Cumulative probability per 100 persons @ 24wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
show 1 more result
19.3 vs 15.3 IPT Cumulative probability per 100 persons @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies 0% (n=424) vs 0.01% (n=426) IPT @ 0wk
event count · % of participants
NCT01380080 · Phase 4 · registry result, not featured evidence
show 3 more results
0.46% (n=424) vs 0.49% (n=426) IPT @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
0.84% (n=424) vs 0.85% (n=426) IPT @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
0.87% (n=424) vs 0.89% (n=426) IPT @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
CD4+ Cell 18 vs 19 IPT cells/uL @ 0wk
event count · cells/uL
NCT01380080 · Phase 4 · registry result, not featured evidence
show 3 more results
74 vs 76 IPT cells/uL @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
121 vs 121 IPT cells/uL @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
176 vs 172 IPT cells/uL @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 86.4% (n=154) vs 83.3% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
99.2% (n=154) vs 97.2% (n=156) ABC/3TC @ 48wk
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA LT 50 Copies 93% (n=154) vs 91.1% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA LT 200 Copies 84.4% (n=154) vs 82.1% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
Snapshot Responder Analysis (Virologic Success)
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 79.9% (n=154) vs 77.6% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
Snapshot Responder Analysis (Virologic Success)
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
Peak VO2 Change mL/Min 2.2 vs 2.8 Combivir or Trizivir kg @ 24wk200/300 mg, Daily, by Mouth
absolute change · kg
NCT00960622 · Phase 4 · registry result, not featured evidence
LDL-C -4.51 vs 9.92 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL -5.3 vs 13.75 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence

+ 12 further endpoints in the CSV export.

Rilpivirine

Virologic Response Rate Lt50 Copies 82.9% (n=346) vs 82.8% (n=344) Efavirenz @ 48wk
responder rate · % of participants
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 287 Participants as posted
show 2 more results
76% (n=346) vs 78.8% (n=344) Efavirenz @ 96wk*
Responder
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 263 Participants as posted
95% (n=258) vs 96.3% (n=271) Efavirenz*
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 245 Participants as posted
Virologic Response Rate Lt50 Copies 82.4% (n=346) vs 81.7% (n=344) Efavirenz @ 48wk
responder rate · % of participants
Virologic Response HIV RNA <50 copies/mL at Wk 48
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 285 Participants as posted
Virologic Response Rate Lt50 Copies 76.6% (n=346) vs 77.9% (n=344) Efavirenz @ 96wk
responder rate · % of participants
Virologic Response, <50 copies/ml
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 265 Participants as posted
Virologic Response Rate Lt400 Copies 85.8% (n=346) vs 85.2% (n=344) Efavirenz @ 48wk
responder rate · % of participants
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 297 Participants as posted
show 1 more result
78.9% (n=346) vs 80.8% (n=344) Efavirenz @ 96wk*
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 273 Participants as posted
CD4+ 195.5 vs 181.6 Efavirenz cells/uL @ 48wk
absolute change · cells/uL
Absolute cell count, Week 48
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
188.6 vs 170.7 Efavirenz cells/uL @ 48wk
Absolute cell count, Week 48
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
CD4+ 220.7 vs 226.7 Efavirenz cells/uL @ 96wk
absolute change · cells/uL
Absolute cell count, Week 96
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
234.5 vs 212 Efavirenz cells/uL @ 96wk
Absolute cell count, Week 96
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
Virological Response 50 Copies TLOVR 85.6% (n=340) vs 81.7% (n=338) Efavirenz @ 48wk
event count · % of participants
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 291 Participants as posted
show 1 more result
79.1% (n=340) vs 76.3% (n=338) Efavirenz @ 96wk*
Responder
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 269 Participants as posted
Virological Response 50 Copies Snapshot 82.6% (n=340) vs 78.4% (n=338) Efavirenz @ 48wk
event count · % of participants
Virologic Response (<50 copies/mL)
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 281 Participants as posted
show 1 more result
76.2% (n=340) vs 75.1% (n=338) Efavirenz @ 96wk*
Virologic response (<50 copies/mL)
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 259 Participants as posted
Virological Response 400 Copies TLOVR 88.2% (n=340) vs 84.6% (n=338) Efavirenz @ 48wk
event count · % of participants
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 300 Participants as posted
show 1 more result
83.2% (n=340) vs 79.9% (n=338) Efavirenz @ 96wk*
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 283 Participants as posted
HIVTSQc 0 vs 0 Current Antiretroviral Regimen (CAR) score @ 4wk
absolute change · score
Total score, Week 4
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
HIVTSQc 1 vs 0 Current Antiretroviral Regimen (CAR) score @ 24wk
absolute change · score
Total score, Week 24
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
HIVTSQc 0.5 vs 0 Current Antiretroviral Regimen (CAR) score @ 48wk
absolute change · score
Total score, Week 48
NCT02429791 · Phase 3 · registry result, not featured evidence · combination

+ 20 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emtricitabine/tenofovir disoproxil fumarate's landscape · Rilpivirine's landscape